Skip to content

#United States

19 NovThu
10 NovTue
  1. Federal Register: DEA and FDA documents (US)40

    DEA proposes 2027 production quotas for Schedule I and II controlled substances and list I chemicals

    The US Drug Enforcement Administration has proposed 2027 aggregate production quotas for Schedule I and II controlled substances and an assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine and phenylpropanolamine. Written comments are due by December 10, 2026, under Docket No. DEA-1730P, after which the Administrator will publish a final order.

5 NovThu
2 NovMon
  1. ClinicalTrials.gov: newly registered trials60

    NYU Langone registers trial of psilocybin-assisted psychotherapy for fear of cancer recurrence in early-stage breast cancer

    NYU Langone Health has registered a double-blind, parallel-design, placebo-controlled, two-centre randomised controlled trial of single-dose psilocybin-assisted psychotherapy in 100 outpatients with early-stage breast cancer. The trial is designed to evaluate efficacy and psychological mechanisms for fear of cancer recurrence (FCR), anxiety and depression distress and quality of life, comparing a single 25mg oral dose of psilocybin with a single 5mg oral dose as an active placebo, both delivered with a psychotherapy platform.

    Why it matters: The registry record sets out a two-centre design with an active placebo, so readers can see how the trial plans to separate psilocybin from expectancy in fear of cancer recurrence.

30 OctFri
  1. Europe PMC: new psychedelic research papers55

    Psilocybin with psychological support for anhedonia in treatment-resistant depression: a randomised controlled pilot trial

    A randomised, double-blind, placebo-controlled pilot trial in 20 participants with treatment-resistant major depressive disorder found no statistically significant between-group difference in anhedonia at the primary week 1 endpoint, with a DARS change difference of 11.2 (95% CI, -1.0 to 23.3; p = 0.073) for psilocybin 25 mg versus 1 mg, both given with psychological support.

5 OctMon
  1. FDA: press announcements (US)62

    FDA seeks public input on early-phase ibogaine trial design

    The US Food and Drug Administration has issued a request for information on approaches it is considering for the design of early-phase clinical trials of ibogaine drug products, and is seeking public comment.

    Why it matters: The request sets out the protocol questions the agency wants answered, including a starting dose cap, so researchers and sponsors can see what evidence the FDA expects before early-phase ibogaine trials proceed.